BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
Heather ThorneLisa DevereuxJason LiKathryn AlsopLiz ChristieCourtney T van GeelenNikki L BurdettKathleen I PishasNoel WoodfordJodie LeditschkeMohamed H M A IzzathKate StrachanGregory YoungRufaro D JaravazaMohammed S MadadinMelanie ArcherJoanna GlengarryLinda IlesAjith RathnaweeraClare HampsonKhamis AlmazrooeiMichael BurkePradeep BandaraDavid RansonEssa SaeediOrla McNallyLinda MileshkinAnne HamiltonSumitra AnandaGeorge Au-YeungYoland AntillShahneen SandhuPeter SavasPrudence A FrancisStephen LuenSherene LoiRoss JennensClare ScottKate MoodieMargaret CummingsAndrew ReidAmy McCart ReedDavid BowtellSunil R LakhaniStephen B FoxPublished in: Histopathology (2023)
Even though a major limitation of this study is that our numbers are small, especially in the breast cancer carrier group, the metastatic patterns of breast and ovarian cancers may be impacted by BRCA1/2 carrier status, suggesting that tumours derived from patients with these mutations use different mechanisms of dissemination. The findings may focus clinical diagnostic imaging for monitoring metastases where whole-body imaging resources are scant.